Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 6Terminated 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Multiple Myeloma 1Liver Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 222pembrolizumab 199Carboplatin 173Cisplatin 168Gemcitabine 167Paclitaxel 154Docetaxel 140Rituximab 137Radiotherapy 137Bevacizumab 137Nivolumab 126Dexamethasone 126Capecitabine 103fludarabine 102Pemetrexed 92fludarabine phosphate 91Fluorouracil 91Doxorubicin 85Oxaliplatin 79Etoposide 77Cytarabine 77Bortezomib 76Erlotinib Hydrochloride 74Leucovorin 72Filgrastim 68Lenalidomide 67Calcium Dobesilate 66Irinotecan 65atezolizumab 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Has results × Tadalafil × Clear all
NCT03785210 2026-02-23

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
22 enrolled 13 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT01374217 2018-12-10

Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Terminated
14 enrolled 8 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡